A practical reference on Intranasal route: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== Third island chain == The third island chain is the final part of the strategy. This island chain begins at the Aleutian Islands and runs south across the center of the Pacific Ocean towards Oceania, through the Hawaiian Islands, American Samoa, and Fiji, to reach New Zealand. Australia serves as the staple between the second and third chains.
Lyodura was a medical product used in neurosurgery that has been shown to have a risk of transmitting Creutzfeldt–Jakob disease, a degenerative neurological disorder that is incurable, from affected donor cadavers to surgical recipients. Lyodura was introduced in 1969 as a product of B. Braun Melsungen AG, a leading hospital supply company based in Germany. The product was used as a quick and effective patch material for surgery on the brain. It was a section of freeze-dried tissue which could be stored for extended periods on hospital shelves and could be made ready for use simply by soaking it in water for a few minutes. As suggested by the name, Lyodura consisted of lyophilized dura mater. Lyophilization is a technical term for freeze-drying. Until 1987, Lyodura was manufacted by mixing together harvested tissue from different donors. The dura matter was then sterilized in batches using gamma radiation and freeze-drying. The manufacturer believed that its sterilization procedure was sufficiently powerful to render any diseases in the tissue harmless and was therefore unconcerned about cross-contamination from CJD-containing tissue to other tissue in the same sterilization vat. It is now believed that of the Lyodura product that was contaminated, almost all was tainted through this process. In 1987, after the first deaths linked to Lyodura, the manufacturer began processing tissue from each individual donor separately to prevent cross-contamination and rinsing it with sodium hydroxide, a proven means of deactivating prions, afterwards.
In 1927, fossils of an ancient wild species of cow, Hanaizumi Moriushi (Leptobison hanaizumiensis), dating from the Paleolithic period about 20,000 years ago, were discovered at the Hanaizumi Site in Ichinoseki City, Iwate Prefecture. The Hanaizumi Moriushi is a species similar to the bison and is said to be close to the steppe bison (Bison priscus) lineage. Fossil bones of Aurochs (Bos primigenius) have also been found in Ichinoseki City. Since Hokkaido and Honshu were land-locked with the Eurasian continent during the Ice Age, these animals came from the continent via Hokkaido. In addition, projectile points made from polished wild cattle bones have been found at the same site, although in small quantities, suggesting that humans existed during this period and that Hanaizumi Moriushi and aurochs were hunted. At the Ohama Site in Goto City, Nagasaki Prefecture, cattle teeth dating to the middle Yayoi period were excavated. Among them were also processed cattle molars. However, this excavation was controversial because it contradicted the statement in Chen Shou's Records of the Three Kingdoms (Wajinden) that there were no cattle or horses in Japan. Later, radiocarbon dating of the excavated cattle molars yielded a date of around 40 AD (±90 years).
Sources: en.wikipedia.org
== External links == "Understanding the RNA World". Exploring Life's Origins. Exploring Origins Project. Ferris, James P. "The Formation of the RNA World". The New York Center for Studies of the Origins of Life, Rensselaer Polytechnic Institute. Archived from the original on March 1, 2012. Altman, Sidney (2001). "The RNA World". NobelPrize.org. Nobel Media. Kuska, Robert (June 2002). "A World Apart" (PDF). HHMI Bulletin. Howard Hughes Medical Institute. pp. 14–19. Archived (PDF) from the original on 2004-05-22. Cech, Thomas R. (2004). "Exploring the New RNA World". NobelPrize.org. Nobel Media. Sutherland JD (April 2010). "Ribonucleotides". Cold Spring Harbor Perspectives in Biology. 2 (4) a005439. doi:10.1101/cshperspect.a005439. PMC 2845210. PMID 20452951. "The Origins of the RNA World". YouTube. Library of Congress. August 5, 2016.
Many proteinogenic and non-proteinogenic amino acids have biological functions beyond being precursors to proteins and peptides. In humans, amino acids also have important roles in diverse biosynthetic pathways. Defenses against herbivores in plants sometimes employ amino acids. Examples:
In the 1935 study, however, Lewis and Pickering were studying patients with palsy of the median nerve when they discovered that skin wrinkling did not occur in the areas of the patients' skin normally innervated by the damaged nerve. This suggested that the nervous system plays an essential role in wrinkling, so the phenomenon could not be entirely explained simply by water absorption. Recent research shows that wrinkling is related to vasoconstriction. Water probably initiates the wrinkling process by altering the balance of electrolytes in the skin as it diffuses into the hands and soles via their many sweat ducts. This could alter the stability of the membranes of the many neurons that synapse on the many blood vessels underneath skin, causing them to fire more rapidly. Increased neuronal firing causes blood vessels to constrict, decreasing the amount of fluid underneath the skin. This decrease in fluid would cause a decrease in tension, causing the skin to become wrinkly. This insight resulted in bedside tests for nerve damage and vasoconstriction. Wrinkling is often scored with immersion of the hands for 30 minutes in water or EMLA cream with measurements steps of 5 minutes, and counting the number of visible wrinkles in time. Not all healthy persons have finger wrinkling after immersion, so it would be safe to say that sympathetic function is preserved if finger wrinkling after immersion in water is observed, but if the fingers emerge smooth it cannot be assumed that there is a lesion to the autonomic supply or to the peripheral nerves of the hand.
Thus, instead of letting the wave propagate through the fuel, the fuel itself is moved through a largely stationary burn wave. This is contrary to many media reports, which have popularized the concept as a candle-like reactor with a burn region that moves down a stick of fuel. By replacing a static core configuration with an actively managed "standing wave" or "soliton" core, TerraPower's design avoids the problem of cooling a highly variable burn region. Under this scenario, the reconfiguration of fuel rods is accomplished remotely by robotic devices; the containment vessel remains closed during the procedure, and there is no associated downtime. In a separate fast-reactor project, the NRC approved a construction permit for TerraPower's Natrium project at Kemmerer, Wyoming, in March 2026. The sodium-cooled fast reactor still required a separate operating licence before it could operate.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.